(CERS) Cerus - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 359m USD | Total Return: 48.4% in 12m

Blood Safety, Pathogen Reduction, Transfusion, Plasma, Platelets
Total Rating 45
Safety 34
Buy Signal -0.43
Medical Devices
Industry Rotation: -6.3
Market Cap: 359M
Avg Turnover: 2.57M USD
ATR: 6.82%
Peers RS (IBD): 81.3
Risk 5d forecast
Volatility69.6%
Rel. Tail Risk-10.3%
Reward TTM
Sharpe Ratio0.85
Alpha12.98
Character TTM
Beta1.271
Beta Downside1.344
Drawdowns 3y
Max DD62.21%
CAGR/Max DD-0.22
EPS (Earnings per Share) EPS (Earnings per Share) of CERS over the last years for every Quarter: "2021-03": -0.1, "2021-06": -0.09, "2021-09": -0.07, "2021-12": -0.05, "2022-03": -0.07, "2022-06": -0.05, "2022-09": -0.05, "2022-12": -0.08, "2023-03": -0.09, "2023-06": -0.06, "2023-09": -0.03, "2023-12": -0.01, "2024-03": -0.05, "2024-06": -0.03, "2024-09": -0.02, "2024-12": -0.01, "2025-03": -0.04, "2025-06": -0.03, "2025-09": -0.0001, "2025-12": -0.01, "2026-03": 0,
EPS CAGR: 22.84%
EPS Trend: 75.5%
Last SUE: 2.58
Qual. Beats: 1
Revenue Revenue of CERS over the last years for every Quarter: 2021-03: 23.379, 2021-06: 31.484, 2021-09: 36.131, 2021-12: 39.865, 2022-03: 37.444, 2022-06: 40.999, 2022-09: 39.571, 2022-12: 44.034, 2023-03: 30.974, 2023-06: 38.853, 2023-09: 39.772, 2023-12: 46.768, 2024-03: 38.365, 2024-06: 45.079, 2024-09: 46.017, 2024-12: 50.809, 2025-03: 43.239, 2025-06: 52.445, 2025-09: 52.698, 2025-12: 57.751, 2026-03: null,
Rev. CAGR: 12.25%
Rev. Trend: 75.5%
Last SUE: -3.46
Qual. Beats: 0

Warnings

Interest Coverage Ratio -1.1 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: CERS Cerus

Cerus Corporation (CERS) is a biomedical company founded in 1991. It develops and commercializes the INTERCEPT Blood System, a technology designed to reduce blood-borne pathogens in donated blood components. This system addresses a critical need in blood safety, a subsector of the healthcare industry.

The INTERCEPT system is applied to platelets, plasma, and red blood cells to inactivate pathogens. Cerus also offers a system for cryoprecipitation, producing pathogen-reduced cryoprecipitated fibrinogen complex for bleeding control. The company utilizes both direct sales and distributors across various global regions.

Understanding the competitive landscape and market penetration of these blood safety products is crucial; further research on platforms like ValueRay can provide detailed insights.

Headlines to Watch Out For
  • INTERCEPT Blood System sales drive revenue growth
  • Regulatory approvals expand product market access
  • Research and development costs impact profitability
  • Global blood supply chain disruptions affect demand
Piotroski VR‑10 (Strict) 3.5
Net Income: -15.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.00 > 0.02 and ΔFCF/TA -3.74 > 1.0
NWC/Revenue: 35.70% < 20% (prev 49.05%; Δ -13.35% < -1%)
CFO/TA 0.02 > 3% & CFO 4.84m > Net Income -15.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.73 > 1.5 & < 3
Outstanding Shares: last quarter (190.6m) vs 12m ago 3.27% < -2%
Gross Margin: 54.47% > 18% (prev 0.55%; Δ 5.39k% > 0.5%)
Asset Turnover: 97.51% > 50% (prev 89.72%; Δ 7.79% > 0%)
Interest Coverage Ratio: -1.07 > 6 (EBITDA TTM -7.56m / Interest Expense TTM 8.34m)
Altman Z'' -15.00
A: 0.33 (Total Current Assets 174.4m - Total Current Liabilities 100.8m) / Total Assets 221.9m
B: -4.87 (Retained Earnings -1.08b / Total Assets 221.9m)
C: -0.04 (EBIT TTM -8.90m / Avg Total Assets 211.4m)
D: -6.89 (Book Value of Equity -1.08b / Total Liabilities 156.9m)
Altman-Z'' Score: -21.23 = D
Beneish M -3.23
DSRI: 0.89 (Receivables 30.4m/29.8m, Revenue 206.1m/180.3m)
GMI: 1.01 (GM 54.47% / 55.21%)
AQI: 0.76 (AQ_t 0.13 / AQ_t-1 0.17)
SGI: 1.14 (Revenue 206.1m / 180.3m)
TATA: -0.09 (NI -15.6m - CFO 4.84m) / TA 221.9m)
Beneish M-Score: -3.23 (Cap -4..+1) = AA
What is the price of CERS shares? As of April 08, 2026, the stock is trading at USD 1.84 with a total of 939,961 shares traded.
Over the past week, the price has changed by +1.10%, over one month by -4.66%, over three months by -11.96% and over the past year by +48.39%.
Is CERS a buy, sell or hold? Cerus has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy CERS.
  • StrongBuy: 4
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CERS price?
Analysts Target Price 5 171.7%
Cerus (CERS) - Fundamental Data Overview as of 03 April 2026
P/S = 1.7433
P/B = 5.6254
Revenue TTM = 206.1m USD
EBIT TTM = -8.90m USD
EBITDA TTM = -7.56m USD
Long Term Debt = 40.5m USD (from longTermDebt, last quarter)
Short Term Debt = 46.2m USD (from shortTermDebt, last quarter)
Debt = 96.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.1m USD (recalculated: Debt 96.9m - CCE 82.9m)
Enterprise Value = 373.4m USD (359.4m + Debt 96.9m - CCE 82.9m)
Interest Coverage Ratio = -1.07 (Ebit TTM -8.90m / Interest Expense TTM 8.34m)
EV/FCF = 337.0x (Enterprise Value 373.4m / FCF TTM 1.11m)
FCF Yield = 0.30% (FCF TTM 1.11m / Enterprise Value 373.4m)
FCF Margin = 0.54% (FCF TTM 1.11m / Revenue TTM 206.1m)
Net Margin = -7.58% (Net Income TTM -15.6m / Revenue TTM 206.1m)
Gross Margin = 54.47% ((Revenue TTM 206.1m - Cost of Revenue TTM 93.8m) / Revenue TTM)
Gross Margin QoQ = 51.51% (prev 53.40%)
Tobins Q-Ratio = 1.68 (Enterprise Value 373.4m / Total Assets 221.9m)
Interest Expense / Debt = 2.03% (Interest Expense 1.96m / Debt 96.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -7.03m (EBIT -8.90m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.73 (Total Current Assets 174.4m / Total Current Liabilities 100.8m)
Debt / Equity = 1.51 (Debt 96.9m / totalStockholderEquity, last quarter 64.2m)
 Debt / EBITDA = -1.86 (negative EBITDA) (Net Debt 14.1m / EBITDA -7.56m)
 Debt / FCF = 12.70 (Net Debt 14.1m / FCF TTM 1.11m)
Total Stockholder Equity = 59.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.39% (Net Income -15.6m / Total Assets 221.9m)
RoE = -26.42% (Net Income TTM -15.6m / Total Stockholder Equity 59.2m)
RoCE = -8.93% (EBIT -8.90m / Capital Employed (Equity 59.2m + L.T.Debt 40.5m))
 RoIC = -4.89% (negative operating profit) (NOPAT -7.03m / Invested Capital 143.8m)
 WACC = 8.57% (E(359.4m)/V(456.3m) * Re(10.45%) + D(96.9m)/V(456.3m) * Rd(2.03%) * (1-Tc(0.21)))
Discount Rate = 10.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.55%
[DCF] Terminal Value 68.11% ; FCFF base≈4.07m ; Y1≈2.67m ; Y5≈1.22m
[DCF] Fair Price = 0.04 (EV 22.0m - Net Debt 14.1m = Equity 7.95m / Shares 192.2m; r=8.57% [WACC]; 5y FCF grow -40.0% → 3.0% )
 [DCF] Fair Price = 0.04 (out of range, set to none)
 EPS Correlation: 75.50 | EPS CAGR: 22.84% | SUE: 2.58 | # QB: 1
Revenue Correlation: 75.54 | Revenue CAGR: 12.25% | SUE: -3.46 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.03 | Chg7d=-0.005 | Chg30d=-0.025 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=-0.06 | Chg7d=+0.010 | Chg30d=-0.035 | Revisions Net=-2 | Growth EPS=+25.0% | Growth Revenue=+13.5%
EPS next Year (2027-12-31): EPS=-0.01 | Chg7d=-0.005 | Chg30d=-0.025 | Revisions Net=-1 | Growth EPS=+91.7% | Growth Revenue=+9.1%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle